Last reviewed · How we verify
Placebo for Revefenacin
This is a placebo, meaning it has no active pharmacological effect.
This is a placebo, meaning it has no active pharmacological effect. Used for Treatment of chronic cough due to idiopathic pulmonary fibrosis.
At a glance
| Generic name | Placebo for Revefenacin |
|---|---|
| Sponsor | Mylan Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological molecules or systems. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Treatment of chronic cough due to idiopathic pulmonary fibrosis
Common side effects
- Injection site reaction
Key clinical trials
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators (PHASE4)
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- Thorough QT (TQT) Study of TD-4208 in Healthy Subjects (PHASE1)
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD (PHASE3)
- A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD (PHASE3)
- A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Revefenacin CI brief — competitive landscape report
- Placebo for Revefenacin updates RSS · CI watch RSS
- Mylan Inc. portfolio CI